

SEP. 22. 2004 5:19PM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 7922 P. 4/25

SEP 22 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
ASTLES, et al.

Examiner: CHANG, CELIA

Art Unit: 1625

Application No.: 09/843,126

Filed: 26 April 2001

Title: CHEMICAL COMPOUNDS

**TELEFAX CERTIFICATE**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on 703-672-9306

September 22, 2004

Date of Transmission

Signature

**TERMINAL DISCLAIMER AND STATEMENT OF COMMON OWNERSHIP**

Mail Stop  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.321(c), the following is submitted:

The petitioner, Aventis Pharmaceuticals Inc., with a place of business at 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807-2854, in the county of Somerset and State of New Jersey represents that it is assignee of the whole and entire right, title and interest of United States Patent Application No. 09/843,126 [hereinafter "the Present Application"].

The petitioner represents that it is assignee of the whole and entire right, title and interest of the Present Application as evidenced by a document assigning rights from inventors to Aventis Pharmaceuticals Products, Inc., recorded in the United States Patent and Trademark Office on July 11, 2001, at Reel 011732, Frame 0021, and a change of name document from Aventis Pharmaceuticals Products, Inc. to Aventis Pharmaceuticals, Inc. submitted to the United States Patent and Trademark Office on September 22, 2004, a copy of which is submitted herewith.

The petitioner also represents that it is assignee of the whole and entire right, title and interest of United States Patent Publication No. 2002/0045613 (hereinafter "the '613 Application").

any other subsequently enacted Public Law or Act which provides for the extension of the term of a patent.


In making the above disclaimer, petitioner does not disclaim any terminal part of any patent granted on the present application prior to the expiration date of the earlier of the term defined in 35 U.S.C. § 154 and of the term as presently shortened by any terminal disclaimer of any patent granted on the '613 Application in the event that said patent later: (a) expires for failure to pay a maintenance fee; (b) is held unenforceable; (c) is found invalid by a court of competent jurisdiction; (d) is statutory disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a); (e) has all claims cancelled by a reexamination certificate; (f) is reissued in any matter; or (g) is otherwise not deemed to provide the rights conveyed by 35 U.S.C. § 154 prior to the expiration of its full statutory term as shortened by any terminal disclaimer, except for the separation of legal title stated above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please charge Deposit Account No. 18-1982 in the amount of \$110.00, pursuant to C.F.R. § 1.20(d), to cover the cost of the filing this Terminal Disclaimer. Any deficiency or overpayment should be charged or credited to Deposit Account No. 18-1982. Two additional copies of this Terminal Disclaimer are enclosed.

Respectfully submitted,

September 22, 2004

  
Raymond S. Parker, III, Ph.D., Reg. No. 34,893  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-5674  
Telefax (908) 231-2626

Aventis Docket No. USCA2413 US NP